--- title: 胰岛素替代给药途径，Profil的重点领域 description: 胰岛素的替代给药途径吸引了广泛的关注。 --- [![profil-logo-wortbild-with claim-4c-offset_1000px-1](https://www.profil.com/hs-fs/hubfs/profil-logo-wortbild-with%20claim-4c-offset_1000px-1.png?width=1000&name=profil-logo-wortbild-with%20claim-4c-offset_1000px-1.png "profil-logo-wortbild-with claim-4c-offset_1000px-1")](https://www.profil.com?hsLang=zh) [![Contact](https://no-cache.hubspot.com/cta/default/481167/1f89c7d1-107f-4c8d-aa7b-f85d0dce14da.png)](https://cta-redirect.hubspot.com/cta/redirect/481167/1f89c7d1-107f-4c8d-aa7b-f85d0dce14da) [Patient information](https://www.profil.de) # [![Header_1077x260px_Diabetes_Treatment](https://www.profil.com/hs-fs/hubfs/BLUE_MOON/Header/Header_1077x260px_Diabetes_Treatment.jpg?width=1077&height=260&name=Header_1077x260px_Diabetes_Treatment.jpg) 胰岛素的替代给药途径 为什么免注射的胰岛素给药途径极具吸引力？挑战又在哪里？](https://www.profil.com/zh/expertise/insulin-alternatives#) ## 模拟生理胰岛素的输送 胰岛素给药的替代途径是一个很具吸引力且重要的研究领域。有效的非注射胰岛素给药途径可能在药理学方面具有相当大的优势。因为通过口、肺、皮肤、胃肠道或腹膜的胰岛素吸收比通过皮下储库更为迅速。这种快速的吸收有望可以模拟健康人在血糖升高后的第一阶段胰岛素分泌。 此外，口服或腹膜给药对肝脏的胰岛素作用要强于外围。迅速作用与不明显的外周高胰岛素血症相结合，可以降低低血糖的风险，并导致较少的体重增加。 ### 挑战与临床试验 尽管胰岛素的替代给药途径为糖尿病患者带来了方便，并且具有药理学方面的优势，但目前只有通过肺部或腹膜吸收的胰岛素给药方式才被商业化利用。需要克服的挑战主要是较低的吸收量，针对这点则需要提高剂量，以及吸收的可变性，这意味着血糖水平降低的幅度可能比预期幅度更大或更小，从而导致低血糖或高血糖的风险更大。 在口服、吸入和皮下给药的胰岛素试验中，Profil研究了早期发展的关键参数和变量，例如生物利用度、生物效能、相互和内部变异性、给药时间和潜在的食物效应。 ![pikto2.png](https://www.profil.com/hs-fs/hubfs/BLUE_MOON/piktos/Icon_NewWebinar.png?width=62&height=70&name=Icon_NewWebinar.png) ### 网络研讨会 网络研讨会点播: **"Alternative Routes** **of** **Insulin Administration"**   [![立即观看](https://no-cache.hubspot.com/cta/default/481167/b763ca09-33a8-4bf0-af9d-685c8f30bedb.png)](https://cta-redirect.hubspot.com/cta/redirect/481167/b763ca09-33a8-4bf0-af9d-685c8f30bedb) ![Dr. Eric Zijlstra](https://www.profil.com/hs-fs/hubfs/BLUE_MOON/content-bilder/Alternative_Route_Insulins/Alternative-Route-Insulins_Mitarbeiter.png?width=154&height=176&name=Alternative-Route-Insulins_Mitarbeiter.png) ### 我们的专家 **Eric Zijlstra 博士** 执行项目总监 [![与他联系](https://no-cache.hubspot.com/cta/default/481167/e3e9734f-2328-4ca2-93fc-e6a0526cbe67.png)](https://cta-redirect.hubspot.com/cta/redirect/481167/e3e9734f-2328-4ca2-93fc-e6a0526cbe67) ![Insulin Pill](https://www.profil.com/hs-fs/hubfs/BLUE_MOON/content-bilder/Alternative_Route_Insulins/Alternative-Route-Insulins_Content1.png?width=470&height=220&name=Alternative-Route-Insulins_Content1.png) [**口服胰岛素** ``` 更多信息 ``` 口服胰岛素将会有哪些优点和挑战？ ](https://www.profil.com/expertise/oral-insulin?hsLang=zh) [**皮内注射胰岛素** ``` 更多信息 ``` 查看皮内注射胰岛素的潜在优点 ](https://www.profil.com/expertise/intradermal-insulin?hsLang=zh) ![blank.jpg](https://www.profil.com/hs-fs/hubfs/BLUE_MOON/piktos/Icon_References.png?width=49&height=49&name=Icon_References.png) #### References We have published with the following sponsors: ![Referenzen](https://www.profil.com/hubfs/BLUE_MOON/content-bilder/Referenzen.gif "Referenzen") [View more](https://www.profil.com/knowledge-center/references?hsLang=zh) ![blank.jpg](https://www.profil.com/hs-fs/hubfs/BLUE_MOON/piktos/Icon_Certificates.png?width=44&height=49&name=Icon_Certificates.png) #### Certificates | ![13485_Zertifikatssiegel_black_A3](https://www.profil.com/hubfs/BLUE_MOON/piktos/ISO_134852016_certificate_blue.png) ISO 13485:2016 ![27001_Zertifikatssiegel](https://www.profil.com/hubfs/BLUE_MOON/piktos/ISO_27001_certificate_.png) ISO 27001 | ![9001:2015_Zertifikatssiegel](https://www.profil.com/hubfs/BLUE_MOON/piktos/ISO_9001-2015_certificate.png) ISO 9001:2015 ![9001:2015_Zertifikatssiegel](https://www.profil.com/hubfs/BLUE_MOON/piktos/BVMA_Logo_Certificate_size.png) BVMA Member | | --- | --- | ![blank.jpg](https://www.profil.com/hs-fs/hubfs/BLUE_MOON/piktos/Icon_Publications.png?width=44&height=49&name=Icon_Publications.png) #### Publications Zijlstra, E. et al., 2014- Oral insulin: a structured approach. J Diabetes Sci Technol 8: 458-465, 2014. [View all](https://www.profil.com/knowledge-center/publications?hsLang=zh) Profil is involved in insulin clinical trials looking at alternative routes of administration, including oral and inhalation. Our trials focus on critical parameters for drugs that may provide physiological insulin delivery that is faster and reduces the risk of adverse effects on the metabolism. ###### Profil Institut für Stoffwechselforschung GmbH Hellersbergstraße 9 · 41460 - Neuss, Germany Telefon +49-2131-4018-345 · marketing@profil.com [Imprint](https://www.profil.com/imprint?hsLang=zh) | [Privacy Policy](https://www.profil.com/privacy?hsLang=zh)